A) Total and B) breakthrough varicella incidence over time, by vaccination strategy. Panel A: Total varicella incidence, including natural and breakthrough cases, over 50 years after the start of universal childhood varicella vaccination. Panel B: Breakthrough varicella incidence over 50 years. In both panels, varicella incidence with strategies E and F were the same as for strategies C and D, respectively. Strategy A: V-MSD (12 months) + V-MSD (15 months); Strategy B: V-GSK (12 months) + V-GSK (15 months); Strategy C: V-MSD (15 months) + V-MSD (48 months); Strategy D: V-GSK (15 months) + V-GSK (48 months); Strategy E: V-MSD (15 months) + MMRV-MSD (48 months); Strategy F: V-GSK (15 months) + MMRV-GSK (48 months).
Research Alert
Press-only preview: https://plos.io/42H3PPj
Article URL: https://journals.plos.org/glob
Article Title: Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness
Image Caption: A) Total and B) breakthrough varicella incidence over time, by vaccination strategy. Panel A: Total varicella incidence, including natural and breakthrough cases, over 50 years after the start of universal childhood varicella vaccination. Panel B: Breakthrough varicella incidence over 50 years. In both panels, varicella incidence with strategies E and F were the same as for strategies C and D, respectively. Strategy A: V-MSD (12 months) + V-MSD (15 months); Strategy B: V-GSK (12 months) + V-GSK (15 months); Strategy C: V-MSD (15 months) + V-MSD (48 months); Strategy D: V-GSK (15 months) + V-GSK (48 months); Strategy E: V-MSD (15 months) + MMRV-MSD (48 months); Strategy F: V-GSK (15 months) + MMRV-GSK (48 months).
Image Credit: Burgess et al., 2023, PLOS Global Public Health, CC-BY 4.0 (https://creativecommons.org/l
Image Link: https://plos.io/3FYjWxX
Author Countries: Denmark, USA
Funding: This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The funder provided support in the form of salaries or consulting fees for CB, SS, TL, CSL, and MP, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interest: MP and SS are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and own stock in Merck & Co., Inc., Rahway, NJ, USA. CB is a contractor with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and was compensated for her work. TL is an employee of MSD Denmark and owns stock in Merck & Co., Inc., Rahway, NJ, USA. CSL was paid an honorarium for consultation on this study.
About PLOS Global Public Health
PLOS Global Public Health is a global forum for public health research that reaches across disciplines and regional boundaries to address some of the biggest health challenges and inequities facing our society today. For more information, visit https://journals.plos.org/glob
Media and Copyright Information
For information about PLOS Global Public Health relevant to journalists, bloggers and press officers, including details of our press release process and embargo policy, visit https://plos.org/press-and-med
PLOS Journals publish under a Creative Commons Attribution License, which permits free reuse of all materials published with the article, so long as the work is cited.
About the Public Library of Science
PLOS is a nonprofit, Open Access publisher empowering researchers to accelerate progress in science and medicine by leading a transformation in research communication. We’ve been breaking boundaries since our founding in 2001. PLOS journals propelled the movement for OA alternatives to subscription journals. We established the first multi-disciplinary publication inclusive of all excellent research regardless of novelty or impact, and demonstrated the importance of open data availability. As Open Science advances, we continue to experiment to provide more opportunities, choice, and context for readers and researchers. For more information, visit http://www.plos.org.
Disclaimer
This press release refers to upcoming articles in PLOS Global Public Health. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
RSS